Nipocalimab improved fatigue by week 2 in patients, supporting its potential as a fast-acting, patient-centered therapy, says Irina Murakhovskaya, MD.
Irina Murakhovskaya, MD
Advertisement
Irina Murakhovskaya, MD, is the chief of hematology and an associate professor at Montefiore Medical Center in the Bronx, NY.
Articles by Irina Murakhovskaya, MD
EHA 2026 highlights include advances in immunotherapy across blood cancers.
Nipocalimab showed rapid responses within 1 week in warm autoimmune hemolytic anemia (wAIHA), as well as a favorable safety profile.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?
2
FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review
3
340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs
4
FDA Approves Atacicept for IgA Nephropathy
5